UCB Investor

You see, UCB wants to be a world leader when it comes to treating ailments related to the immune and central nervous systems (CNS).


Invests into

Total Funding: 202213820.0
Acquisitions Number: Made Acquisitions
Headquarters: Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Funding Status: IPO
Employee Number: 5001-10000
Estimated Revenue: $1B to $10B
Investment Stage: Early Stage Venture
Last Funding Type: Post-IPO Equity
Number Of Exists: 3
Last Funding Date: 2022-05-24
Investors Number: 1
Founded Date: 1928-01-01
Industry: Biotechnology